These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma. Mulgaonkar A; Elias R; Woolford L; Guan B; Nham K; Kapur P; Christie A; Tcheuyap VT; Singla N; Bowman IA; Stevens C; Hao G; Brugarolas J; Sun X Clin Cancer Res; 2022 Nov; 28(22):4907-4916. PubMed ID: 36074149 [TBL] [Abstract][Full Text] [Related]
3. Preclinical PET imaging with the novel human antibody Kelly MP; Makonnen S; Hickey C; Arnold TC; Giurleo JT; Tavaré R; Danton M; Granados C; Chatterjee I; Dudgeon D; Retter MW; Ma D; Olson WC; Thurston G; Kirshner JR J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483343 [TBL] [Abstract][Full Text] [Related]
4. Bensch F; van der Veen EL; Lub-de Hooge MN; Jorritsma-Smit A; Boellaard R; Kok IC; Oosting SF; Schröder CP; Hiltermann TJN; van der Wekken AJ; Groen HJM; Kwee TC; Elias SG; Gietema JA; Bohorquez SS; de Crespigny A; Williams SP; Mancao C; Brouwers AH; Fine BM; de Vries EGE Nat Med; 2018 Dec; 24(12):1852-1858. PubMed ID: 30478423 [TBL] [Abstract][Full Text] [Related]
5. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497 [TBL] [Abstract][Full Text] [Related]
6. Immuno-PET Imaging of Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426 [TBL] [Abstract][Full Text] [Related]
7. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report. Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242 [TBL] [Abstract][Full Text] [Related]
8. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. McGregor BA; McKay RR; Braun DA; Werner L; Gray K; Flaifel A; Signoretti S; Hirsch MS; Steinharter JA; Bakouny Z; Flippot R; Wei XX; Choudhury A; Kilbridge K; Freeman GJ; Van Allen EM; Harshman LC; McDermott DF; Vaishampayan U; Choueiri TK J Clin Oncol; 2020 Jan; 38(1):63-70. PubMed ID: 31721643 [TBL] [Abstract][Full Text] [Related]
9. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610 [TBL] [Abstract][Full Text] [Related]
10. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390 [TBL] [Abstract][Full Text] [Related]
11. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647 [TBL] [Abstract][Full Text] [Related]
12. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. Bansal A; Pandey MK; Barham W; Liu X; Harrington SM; Lucien F; Dong H; Park SS; DeGrado TR Nucl Med Biol; 2021; 100-101():4-11. PubMed ID: 34119742 [TBL] [Abstract][Full Text] [Related]
13. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026 [TBL] [Abstract][Full Text] [Related]
14. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma. Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Chelator-to-Antibody Ratio on Development of Tsai SC; Farn SS; Lo WL; Ou Yang FY; Kang YC; Chen LC; Chen KT; Liao JW; Kung JY; Chen JT; Huang FJ Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138961 [No Abstract] [Full Text] [Related]
16. In Vivo Imaging of the Programmed Death Ligand 1 by González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151 [TBL] [Abstract][Full Text] [Related]
17. Soluble PD-L1 as an early marker of progressive disease on nivolumab. Mahoney KM; Ross-Macdonald P; Yuan L; Song L; Veras E; Wind-Rotolo M; McDermott DF; Stephen Hodi F; Choueiri TK; Freeman GJ J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131863 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293 [TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706 [TBL] [Abstract][Full Text] [Related]
20. Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma. Sato K; Ono T; Sato F; Kawahara A; Azuma K; Kawaguchi T; Akiba J; Umeno H Oral Oncol; 2020 Feb; 101():104366. PubMed ID: 31300273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]